PARP Inhibitor Market to Exhibit a CAGR of 27.4% over the Forecast Period | Key Players: Johnson & Johnson, AstraZeneca Plc., GlaxoSmithKline plc., Clovis Oncology Inc., Pfizer, Inc.

The Global PARP Inhibitor Market was worth USD 924 million in 2018 and is expected to expand at a CAGR of 27.4% over the forecast period. PARP is a poly (ADP-ribose) polymerase inhibitor was designed to target cancer cells with BRCA1/2 mutations. Anti-cancer drugs known as poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi) compete with nicotinamide (NAD+) for the catalytically active site of PARP molecules. According to World Health Organization figures from 2018, cancer is the second leading cause of death worldwide, accounting for 9.6 million deaths in 2018. In 2018, cancer claimed the lives of approximately 1 in every 6 people worldwide. Several PARP inhibitors are currently licensed to treat BRCA1/2 mutated breast, ovarian, pancreatic, and prostate cancers. Recent research suggests that PARP inhibitors may have a much broader range of applications. Treatment of tumors with alternative HR defects or mutations in other DNA damage response genes falls under this category.

Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-60838?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Over the forecast period, the global PARP inhibitor market is expected to expand due to increased government support for spreading knowledge about novel cancer therapies. Olaparib was recently approved by the FDA to treat HRD-positive metastatic castration-resistant prostate cancer. Rucaparib (Rubraca), Niraparib (Zejula), and Talazoparib (Talzenna) are some of the other PARP inhibitors that have been licenced for use in clinical trials. Rucaparib was approved by the FDA in May 2020 for the treatment of BRCA1/2 mutated metastatic castration-resistant prostate cancer (Abida et al., 2019).

Growth Drivers that Support the Global PARP Inhibitor Market:

• Since the only PARP inhibitor approved in the market is Lynparza from AstraZeneca, and many PARP inhibitors are in late stage pipelines that are showing promising results in recently released clinical trials details, the lynparza market is expected to dominate the market in the drug category.

• According to a study released by the Centers for Disease Control and Prevention (CDC) in 2014, there were nearly 21 million cancer patients diagnosed in the United States. By the end of 2024, the figure is estimated to reach 25.4 million. Asia, Africa, and South America account for more than 60% of all new cancer cases worldwide.

• A significant number of diseases and illnesses are linked to ageing. Cancer affects the bulk of the elderly population. According to the Administration for Community Living, the United States' geriatric population (people aged 65 and up) totaled 46.2 million in 2014. As a result, the global PARP inhibitors market is expected to grow during the forecast period due to a rise in the elderly population.

• In the global PARP inhibitor industry, North America is the market leader. The region's dominance is due to increasing R&D activities by key players, better reimbursement policies, and the availability of advanced healthcare infrastructure, all of which contribute to the region's maintaining a larger market share in the global PARP inhibitors market over the forecast period.

• PARP inhibitors are currently being tested in clinical trials alongside other therapies such as radiation therapy, chemotherapy, and angiogenesis inhibitors (which stop tumours from growing new blood vessels).

• Currently, clinical trials are being conducted in patients with prostate cancer, pancreatic cancer, triple-negative breast cancer, and other cancer forms to see whether PARP inhibitors will help them.

• The emerging research on the use of PARP inhibitors in patients with BRCA-associated epithelial ovarian cancer (EOC) is motivating and exciting as we step through the age of personalised medicine. There will be further research and development into the use and function of PARP inhibitors in the clinic over the next few years. To make the best use of these exciting agents and improve outcomes for women with EOC, careful clinical trial design and the production and validation of biomarkers are needed.

Speak to analyst before buying this report: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60838?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Major companies functioning in the global PARP Inhibitor Market are Johnson & Johnson, AstraZeneca Plc., GlaxoSmithKline plc., Clovis Oncology Inc., Pfizer, Inc., AbbVie Inc., Merck KGaA, Bristol - Myers Squibb, Genentech, Inc., Sierra Oncology, Inc., Repare Therapeutics Inc., Ono Pharmaceutical Co., LTD., Karyopharm Therapeutics Inc., and Jiangsu Hengrui Medicine Co., Ltd.

Market Segmentation:

By Drug
• Lynparza
• Niraparib
• Rucapairb
• Talazoparib
• Veliparb

By Indication
• Overian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America
o By Country (US, Canada, Mexico)
o By Drug
o By Indication
o By Distribution Channel

Western Europe
o By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
o By Drug
o By Indication
o By Distribution Channel

Eastern Europe
o By Country (Russia, Turkey, Rest of Eastern Europe)
o By Drug
o By Indication
o By Distribution Channel

Asia Pacific
o By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
o By Drug
o By Indication
o By Distribution Channel

Middle East
o By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
o By Drug
o By Indication
o By Distribution Channel

Rest of the World
o By Region (South America, Africa)
o By Drug
o By Indication
o By Distribution Channel

Contact:
Quince Market Insights
Office No- A109
Pune, Maharashtra 411028
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com

ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.